CAMP4 Therapeutics CorporationCAMPNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank69
5Y CAGR+2.6%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+2.6%/yr
Long-term compound
Percentile
P69
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 3.72% |
| Q3 2025 | 9.90% |
| Q2 2025 | 9.71% |
| Q1 2025 | -18.72% |
| Q4 2024 | 22.97% |
| Q3 2024 | 16.53% |
| Q2 2024 | 4.40% |
| Q1 2024 | 11.37% |
| Q4 2023 | -1.88% |
| Q3 2023 | -87.18% |
| Q2 2023 | -1.19% |
| Q1 2023 | -4.28% |
| Q4 2022 | -9.92% |
| Q3 2022 | -1.41% |
| Q2 2022 | 8.78% |
| Q1 2022 | -5.86% |
| Q4 2021 | 3.05% |
| Q3 2021 | 0.39% |
| Q2 2021 | -1.89% |
| Q1 2021 | -9.39% |
| Q4 2020 | 3.27% |
| Q3 2020 | 3.15% |
| Q2 2020 | -6.32% |
| Q1 2020 | -2.14% |
| Q4 2019 | 0.71% |
| Q3 2019 | -10.49% |
| Q2 2019 | 431.09% |
| Q1 2019 | -75.27% |
| Q4 2018 | -0.20% |
| Q3 2018 | -5.47% |
| Q2 2018 | 0.29% |
| Q1 2018 | 7.86% |
| Q4 2017 | 3.02% |
| Q3 2017 | -19.98% |
| Q2 2017 | -1.48% |
| Q1 2017 | 22.12% |
| Q4 2016 | 0.85% |
| Q3 2016 | -12.18% |
| Q2 2016 | 68.05% |
| Q1 2016 | 45.30% |